Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Zymeworks

Hedge Fund Managers Are Aggressively Buying Biotech Stocks Despite Trump Hinting at Pharma Tariffs

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce tariffs on the industry soon.

International Business Times

Zymeworks in Focus for Insider Activity: Catalysts Ahead

Zymeworks in Focus for Insider Activity: Catalysts Ahead

Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.

Analyst Ratings for Zymeworks

Analyst Ratings for Zymeworks

Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Zymeworks Turns Down All Blue's Hostile Bid

Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons.

Where Zymeworks Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022

48 Stocks Moving In Friday's Mid-Day Session

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

inkl

Read news from The Economist, FT, and more,
with one subscription

Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points

Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday.

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

Here's a roundup of top developments in the biotech space over the last 24 hours.

28 Stocks Moving in Friday's Pre-Market Session

28 Stocks Moving in Friday's Pre-Market Session

Gainers Zymeworks Inc. (NASDAQ: ZYME) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per share.

Zymeworks: Q4 Earnings Insights

Zymeworks: Q4 Earnings Insights

Zymeworks (NYSE:ZYME) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Zymeworks beat estimated earnings by 16.67%, reporting an EPS of $-0.95 versus an estimate of $-1.14.

A Preview Of Zymeworks's Earnings

A Preview Of Zymeworks's Earnings

Zymeworks (NYSE:ZYME) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Zymeworks will report an earnings per share (EPS) of $-1.14.

Zymeworks Raises $100M Via Equity Issued At 14% Discount

Zymeworks Raises $100M Via Equity Issued At 14% Discount

Zymeworks Inc (NYSE: ZYME) has priced its underwritten public offering of 9.16 million common shares, pre-funded warrants to purchase up to 3.34 million shares.

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities

Zymeworks Inc (NYSE: ZYME) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company.

People

114,597 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

AstraZeneca Plc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

270,408 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play